SUMMARY In a large family with 37 members with multiple exostoses, only one person has developed sarcomatous degeneration of a lesion. Our review of published reports revealed great variation in the incidence of malignancy in multiple exostoses (10 to 25 %). Most studies had sampling errors leading to the apparent overstatement of risk. In large pedigrees with essentially complete ascertainment of affected subjects, the risk of malignancy is nearer 3 % or less. This lower risk for malignancy may be more appropriate in counselling affected subjects.
Hereditary multiple exostoses is an autosomal dominant trait characterised by numerous cartilage capped lesions located in areas of actively growing bone.1-3 Although exostoses may cause complications through the compression of local tissues, the major threat to life derives from the malignant degeneration of the lesions. Earlier studies of families with multiple exostoses4-9 reported on the wide variation in the severity of the trait and the risk of malignant transformation. We have recently had the opportunity to follow and treat an extended family of Pennsylvania German extraction. Because these families are large and stable, we were able to trace five generations and identify 37 cases of multiple exostoses out of 104 subjects is in fact low, albeit greater than the risk to the general population. The relatively low incidence of malignancy in some families and apparent high incidence in others may reflect allelic forms of multiple exostoses, chance occurrence, environmental effects, epistasis, or some combination of these factors.
Although most cases of sarcomatous degeneration occur in adults, it has been reported in subjects as young as 10 years of age.4 Knight5 reported bony sarcomatous changes in three brothers with the disease. Once the diagnosis is established, it is only prudent to alert the family of the potential risk of malignancy. An enlarging lesion at any age needs immediate attention. In a large family with many affected members, the risk of malignancy may be estimated from previous familial occurrences. For those subjects who represent new mutations (about 40% of the newly detected affected subjects), the risk of malignancy is probably about 3 % and perhaps even less.
Discussion
Physicians are frequently asked about the exact risk of bony malignancy by anxious subjects with hereditary multiple exostoses. A careful family history may be the most important factor for predicting the probable risk of malignant degeneration. The reported incidence of malignant degeneration of the exostoses varies greatly, ranging from 3 to 25 %. Chondrosarcoma appeared in three of the 28 patients studied by Jaffe10 at the Hospital for Joint Disease. However, only those family members evaluated at the hospital were included in this estimate and thus ascertainment was not complete. Based on a review of 272 cases of multiple exostoses treated at the Mayo Clinic, Dahlin' 
